Hasil Pencarian  ::  Simpan CSV :: Kembali

"Kegiatan pemantauan terapi obat di Puskemas Jatinegara bertujuan memastikan efek terapi obat tercapai dan meminimalisir efek samping obat. Pasien hamil dan menyusui termasuk dalam kriteria pemantauan karena adanya resiko penggunaan obat tertentu yang berpengaruh pada kesehatan ibu, janin atau bayi. Petugas farmasi perlu mengkaji keamanan obat terlebih dahulu sebelum melakukan penyerahan obat, sehingga untuk meningkatkan efisiensi dan efektivitas pelayanan dilakukan pengelompokan kategori keamanan obat ibu hamil dan menyusui. Metode penyelesaian dilakukan pengumpulan, penyeleksian, pengkajian daftar obat oral dari formularium puskesmas sesuai kategori keamanan obat ibu hamil dan menyusui, serta membuat dan memberi penandaan kategori obat ibu hamil menurut acuan Food Drug Administration (1979). Berdasarkan hasil penggolongan, persentase kategori keamanan obat ibu hamil di Puskesmas Jatinegara diperoleh 4,04% kategori A; 19,19% kategori B; 65,65 kategori C; 8,08% kategori D; dan 7,07% kategori X. Sedangkan keamanan obat ibu menyusui didapatkan persentase 5,35% kompatibel dengan menyusui; 14,14% kompatibel dengan menyusui dan perlu diperhatikan efek samping pada bayi; 22,22% hindari jika memungkinkan dan perhatikan efek samping pada bayi; 3,03% hindari jika memungkinkan dan dapat menghambat laktasi; dan 13,13% kontraindikasi. Kegiatan penandaan label kategori keamanan obat A, B, C, D, dan X ibu hamil dilakukan di rak obat Puskesmas Jatinegara.

---

Monitoring drug therapy at Jatinegara Public Health aims to ensure the therapeutic effects of drugs are achieved and minimize the side effects of drugs. Pregnant and breastfeeding patients are included in the monitoring criteria because of the risk of using certain drugs that affect the health of the mother, fetus or baby. Pharmacy officers need to assess drug safety first before dispensing drugs, so that to increase the efficiency and effectiveness of services, drug safety categories for pregnant and breastfeeding mothers are grouped. The method was to collect, select, review the list of oral drugs from the formulary of public health according to the drug safety category of pregnant and lactating women, and make and mark the category of drugs for pregnant women according to Food Drug Administration (1979). Based on the classification, the percentage of drug safety categories for pregnant women at the Jatinegara Public Health obtained 4.04% category A; 19.19% category B; 65.65 category C; 8.08% category D; and 7.07% category X. The safety of drugs for breastfeeding obtained 5.35% compatible with breastfeeding; 14.14% compatible with breastfeeding and need to pay attention to side effects on the baby; 22.22% avoid if possible and pay attention to side effects on the baby; 3.03% avoid if possible and can inhibit lactation; and 13.13% contraindications. Labeling drug safety categories A, B, C, D, and X for pregnant women was carried out at Jatinegara Public Health drug shelf."

"Koledokolitiasis adalah keadaan tersumbatnya saluran Common Bile Duct oleh batu empedu yang dapat menyebabkan komplikasi infeksi saluran empedu dan ikterus. Koledokolitiasis dialami oleh pasien X yang merupakan pasien geriatri dengan multi-penyakit dan polifarmasi, sehingga membutuhkan pemantauan terapi obat karena pasien berpotensi rentan tidak patuh pengobatan, terjadi efek samping obat ataupun penurunan fungsi organ tubuh. Metode penelitian dilakukan dengan menelusuri rekam medis, melakukan pemantauan terapi obat dan visite pasien X. Hasil pemantauan terapi obat pasien X ditemukan potensi interaksi obat mayor antara cilostazol dengan lansoprazole, ibuprofen, dan siprofloksasin yang berakibat pendarahan dan interaksi antara simvastatin dengan siprofloksasin dan cilostazol yang berpotensi menimbulkan rhabdomyolisis. Menurut hasil visite, pasien tidak mengalami gejala klinis pendarahan atau rhabdomyolisis. Tes laboratorium aPTT dan PT direkomendasikan apabila pasien X mengalami gejala pendarahan untuk mempertimbangkan penurunan dosis cilostazol. Selain itu, pasien diketahui menggunakan lansoprazole dengan jangka waktu melebihi ketentuan BEERs Criteria, maka dapat direkomendasikan pertimbangan penghentian penggunaan lansoprazole karena berpotensi osteoporosis dan terinfeksi C. difficile.

---

Choledocholithiasis is a condition where the Common Bile Duct is blocked by gallstones which can lead to complications of bile duct infection and jaundice. Choledocholithiasis is experienced by patient X who is a geriatric patient with multi-disease and polypharmacy, so it requires monitoring of drug therapy because patients are potentially vulnerable to non-compliance with treatment, drug side effects or decreased organ function. The research method was carried out by tracing medical records, monitoring drug therapy and visiting patient X. The results of monitoring patient X's drug therapy found potential major drug interactions between cilostazol with lansoprazole, ibuprofen, and ciprofloxacin which resulted in bleeding and interactions between simvastatin with ciprofloxacin and cilostazol which had the potential to cause rhabdomyolysis. According to the results of the visit, the patient did not experience clinical symptoms of bleeding or rhabdomyolysis. Laboratory tests of aPTT and PT were recommended if patient X experienced bleeding symptoms to consider decreasing the dose of cilostazol. In addition, the patient was known to use lansoprazole for a period exceeding the provisions of the BEERs Criteria, so it can be recommended to consider discontinuing the use of lansoprazole because of the potential for osteoporosis and C. difficile infection."

"Pelayanan informasi obat mencakup kegiatan pembuatan dan penyebaran leaflet dengan tujuan memberikan informasi dan mengedukasi pasien atau tenaga kesehatan mengenai penyakit dan obatnya. Leaflet sebagai media informasi obat dapat meningkatkan efisiensi petugas farmasi dalam menyediakan informasi kepada pasien, maka dilakukan pembuatan leaflet dengan topik konstipasi untuk menunjang pelayanan informasi obat konstipasi di Apotek Kimia Farma 352 Margonda. Metode pembuatan leaflet dilakukan dengan mengumpulkan materi, membuat dan mencetak pamflet konstipasi. Leaflet konstipasi berisi informasi singkat terkait pengertian, gejala, penyebab, komplikasi, pencegahan, terapi farmakologis dan non-farmakologis konstipasi. Leaflet juga diberi desain yang menarik untuk meningkatkan minat pembaca sehingga dapat membantu petugas apotek untuk memberikan manfaat pelayanan farmasi klinis dalam meningkatkan kesehatan, mencegah penyakit, penyembuhan penyakit, dan menyediakan informasi obat kepada pasien mengenai konstipasi.

---

Drug information services include the activities of making and distributing leaflets with the aim of providing information and educating patients or health workers about diseases and their medicines. Leaflets as a medium for drug information can increase the efficiency of pharmacy staff in providing information to patients, so leaflets were made on the topic of constipation to support constipation drug information services at Kimia Farma 352 Margonda Pharmacy. The method for making leaflets is done by collecting materials, making and printing constipation pamphlets. The constipation leaflet contains brief information regarding the definition, symptoms, causes, complications, prevention, pharmacological and non-pharmacological therapy of constipation. The leaflet is also given an attractive design to increase reader interest so that it can help pharmacy staff to provide the benefits of clinical pharmacy services in improving health, preventing disease, curing disease, and providing drug information to patients regarding constipation."

"Produk farmasi perlu disimpan sesuai suhu penyimpanan yang dianjurkan untuk menjaga kualitas dan mempertahankan kestabilan obat selama masa simpan hingga digunakan konsumen. Pemetaan suhu dalam CDOB tahun 2020 dilakukan secara berkala untuk menjamin penyimpanan produk sesuai ketentuan penyimpanannya. PT Era Caring Indonesia memiliki 5 data logger di ambient room dan cool room yang tidak sesuai dengan pedoman WHO (2015) karena tidak mewakili hasil pemetaan suhu. Pemetaan suhu ulang dilakukan untuk menentukan titik suhu tertinggi dan terendah di ambient room dan cool room sesuai standar WHO. Metode penelitian dilakukan perencanaan tata letak data logger di ambient room dan cool room, memasang data logger (Elitech®) terkalibrasi sesuai perencanaan selama 7 hari setiap jam dan cool room selama 3 hari setiap jam, mengunduh data suhu pada software, dan menganalisa hasil pemetaan suhu. Berdasarkan hasil pemetaan diperoleh suhu tertinggi 26,0°C pada DL-17 dan suhu terendah 24,9°C pada DL-20 pada ambient room (25-30°C). Cool room (15-25°C) memiliki suhu tertinggi 23,3°C pada DL-9 dan suhu terendah 20,3°C pada DL-18. Pemetaan suhu memenuhi persyaratan suhu pada setiap ruangannnya, Namun saat pemetaan suhu berlangsung, daya baterai data logger rendah sehingga jumlah data logger tidak memadai dan tidak mewakili hasil pemetaan suhu gudang sesuai ketentuan WHO (2015).

---

Pharmaceutical products need to be stored according to the recommended storage temperature to maintain quality and drug stability during the shelf life until consumer use. Temperature mapping in CDOB 2020 is carried out periodically to ensure product storage complies with storage requirements. PT Era Caring Indonesia has 5 data loggers in the ambient room and cool room which do not comply with WHO guidelines (2015) because it do not represent the results of temperature mapping. Re-temperature mapping was carried out to determine the highest and lowest temperature points in the ambient room and cool room according to WHO standards. The research method was planning the layout of the data logger, installing a calibrated data logger (Elitech®) according to the plan for 7 days every hour and in the cool room for 3 days every hour, downloading the temperature data into the software, and analyzing the temperature mapping results. Based on the results, the highest temperature was 26.0°C on DL-17 and the lowest temperature was 24.9°C on DL-20 in the ambient room (25-30°C). The cool room (15-25°C) has the highest temperature of 23.3°C on DL-9 and the lowest temperature of 20.3°C on DL-18. Temperature mapping meets the temperature requirements in each room. However, when temperature mapping is taking place, the data logger battery power is low so that the number of data loggers is inadequate and does not represent the results of warehouse temperature mapping according to WHO regulations (2015)."

"Peralatan sensor empty pocket mesin pengemas dan alarm checkweigher PT Medifarma Laboratories memiliki kegiatan rekualifikasi kinerja yang terjadwal di periode 2023 atau setiap 5 tahun sekali. Rekualifikasi dilakukan dengan tujuan menjamin status peralatan terkualifikasi sesuai persyaratan, memantau hasil produk tetap terkendali jika tidak terdapat maupun terdapat perubahan pada alat, dan menjamin kualitas produk pada proses pengemasan. Rekualifikasi peralatan dilakukan dengan menyiapkan protokol, mengkoordinasikan jadwal rekualifikasi, melakukan dan mendokumentasikan hasil rekualifikasi peralatan oleh departemen Quality Assurance validasi dan kalibrasi, engineering dan produksi, serta menyiapkan laporan rekualifikasi. Berdasarkan hasil rekualifikasi kinerja, peralatan sensor empty pocket di mesin pengemas memenuhi spesifikasi kriteria keberterimaan pada parameter alarm berbunyi dan mesin mati secara otomatis pada setiap kantong strip yang kosong. Hasil parameter kualifikasi alarm checkweigher dalam mendeteksi berat corr box pengemas tersier juga memenuhi spesifikasi pada setiap kriteria keberterimaannya. Peralatan sensor empty pocket di mesin pengemas dan alarm pada checkweigher disimpulkan memenuhi kriteria keberterimaan dan peralatan masih berstatus terkualifikasi.

---

Empty pocket sensor for packaging machines and alarm on checkweigher at PT Medifarma Laboratories has performance requalification activities scheduled for the 2023 period or once every 5 years. Requalification is carried out with the aim of ensuring the status of qualified equipment in accordance with requirements, monitoring product results to remain under control if there are no or changes to the equipment and guaranteeing product quality during the packaging process. Equipment requalification is carried out by preparing protocols, coordinating the requalification schedule, carrying out and documenting the results of equipment requalification by the Quality Assurance validation and calibration, engineering, and production departments, as well as preparing requalification reports. Based on the performance requalification results, the empty pocket sensor equipment in the packaging machine meets the acceptance criteria specifications in the parameters of the alarm sounding and the machine turning off automatically for each empty strip pocket. The results of the checkweigher alarm qualification parameters in detecting the corr box weight of tertiary packaging also meet the specifications for each acceptance criterion. The empty pocket sensor equipment on the packaging machine and the alarm on the checkweigher were concluded to meet the acceptance criteria and the equipment still had qualified status."